Firefly Neuroscience (NASDAQ: AIFF) Reports 291% Increase in TMS Center Customer Brain Scan Volumes

Firefly Neuroscience announced a nearly four-fold increase in TMS center customer clinical assessments using its FDA-cleared Evoke AI-powered EEG/ERP platform. The platform combines quantitative EEG and event-related potentials to help clinicians assess brain activity and tailor treatments for psychiatric and behavioral health conditions. The company continues to expand adoption among TMS centers while building its proprietary database of over 200,000 EEG/ERP brain scans.